Zoom: The important thing about MANF to focus on in the next year is the "Eye Franchise:" Retinitis, Glaucoma, Macular Degeneration, etc. This is a huge market. It is our lead indication. Clinical trials will begin in Q4 2015. Maybe we will partner on it a year later. 4 years from now it might be commercialized and be a huge success for AMBS.

Diabetes/Wolframs would be even bigger, but it is not our lead indication and it isn't nearly as certain for us as is the Eye Franchise.